Dr. Reddy’s Ends Novartis India Brand Distribution Pact, Plans Transition by September 2026
I'm LongbridgeAI, I can summarize articles.Dr. Reddy’s Laboratories has terminated its brand distribution pact with Novartis India, effective September 30, 2026, following a change in Novartis's controlling shareholding. The company will maintain current commercialization arrangements until the transition date to ensure continuity for patients and prescribers. This move allows Dr. Reddy’s to reassess partnership terms amid ownership changes. Analyst ratings remain mixed, with some maintaining a 'Buy' recommendation while AI analysis suggests a 'Neutral' stance due to solid financials but weakened near-term trends.
Dr Reddy’s Laboratories ( (RDY) ) has shared an announcement.
On August 7, 2026, Dr. Reddy’s Laboratories disclosed that it has terminated its February 11, 2022 agreement with Novartis India Limited for the distribution and promotion of select brands in India, following a change in Novartis India’s controlling shareholding. The company will continue to commercialize the affected brands until September 30, 2026, signaling a planned transition that may reshape its partnership structure in the Indian market while maintaining short-term continuity for prescribers and patients.
The termination, formally communicated to the National Stock Exchange, BSE, NYSE and NSE IFSC, underscores Dr. Reddy’s willingness to revisit collaboration terms when counterparties’ ownership changes. Stakeholders in India’s pharmaceutical distribution chain can expect the current brand arrangements to remain in place through the third quarter of 2026, after which Dr. Reddy’s may pursue alternative commercialization or partnership strategies for these products.
The most recent analyst rating on (RDY) stock is a Buy
with a $1540.00 price target.
To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock,
see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
RDY scores in the low 60s primarily due to solid underlying financial quality (healthy balance sheet and ongoing profitability) but weakened near-term cash flow and margin/revenue trends. Technicals are a notable drag with the stock trading below all major moving averages. Valuation is middling with a ~29 P/E and modest dividend yield, while the latest earnings call was mixed—constructive guidance for a second-half recovery but with clear execution and regulatory risks tied to semaglutide and the biologics site.
To see Spark’s full report on RDY stock,
click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a global pharmaceutical company based in Hyderabad, India, with shares listed in Mumbai and on the New York Stock Exchange. It focuses on developing, manufacturing and marketing generic and branded medicines, serving both domestic and international markets with a broad portfolio of therapeutic products.
Average Trading Volume: 2,701,769
Technical Sentiment Signal: Hold
Current Market Cap: $10.28B
Learn more about RDY stock on TipRanks’ Stock Analysis page.